<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seventy-seven patients were identified with Rare recurring (excluding 11q23, 21q22, inv(16), and t(15;17)) chromosome abnormalities among 511 patients with treatment-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> accepted from centers in the United States, Europe, and Japan </plain></SENT>
<SENT sid="1" pm="."><plain>The abnormality subsets included 3q21q26 (17 patients), 11p15 (17 patients), t(9;22)(q34;q11) (10 patients), 12p13 (9 patients), t(8;16)(p11;p13) (9 patients), and an "other" subset, which included t(6;9)(p23;q34) (3 patients), t(10;11)(p13;q13 approximately q21) (3 patients), t(1;17)(p36;q21) (2 patients), t(8;14)(q24;q32) (2 patients), t(11;19)(q13;q13) (2 patients), t(1;3)(p36;q21) (2 patients), and t(3;5)(q21;q31) (1 patient) </plain></SENT>
<SENT sid="2" pm="."><plain>Increased karyotypic complexity with additional balanced and unbalanced rearrangements was observed in 70% of cases </plain></SENT>
<SENT sid="3" pm="."><plain>Among 54 cases with secondary abnormalities, chromosome 5 and/or 7 abnormalities were observed in 59% </plain></SENT>
<SENT sid="4" pm="."><plain>The most frequent <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary diseases</z:e> were <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (24 cases), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin disease</z:e> (14 cases), non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (10 cases), and de novo ALL (5 cases) </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-seven patients received <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> plus <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> with or without radiation therapy </plain></SENT>
<SENT sid="6" pm="."><plain>The presenting diagnosis was t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in 47 cases, t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in 23 cases (10 progressed to t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and t-ALL in seven cases, five of whom had a t(9;22) </plain></SENT>
<SENT sid="7" pm="."><plain>The median latency time from initiation of original therapy to therapy-related disease diagnosis was quite long (69 months), and the overall median survival from the date of therapy-related disease diagnosis was very short (7 months) </plain></SENT>
<SENT sid="8" pm="."><plain>The 1-year survival rate was 34 +/- 7%, with no significant differences among subsets </plain></SENT>
<SENT sid="9" pm="."><plain>Comparison with previously reported cases showed increased karyotypic complexity and adult presentation of pediatric-associated chromosome abnormalities </plain></SENT>
</text></document>